Impact of Toxin-Specific Antibodies on the Adjuvanticity and Inflammatory Effects Induced by Parenterally Administered Escherichia coli heat-Labile Toxin

Introduction: Heat-labile toxins (LT), produced by enterotoxigenic Escherichia coli (ETEC) strains, exert potent adjuvant effects when admixed or linked to antigens delivered via mucosal, transcutaneous or parenteral routes. There is limited information regarding the impact of preexisting immunity on the immunomodulatory properties of LT, which is frequently observed among people infected with ETEC. Aims: In the present study, we evaluated the effect of anti-LT antibodies on the adjuvant and inflammatory activities triggered by LT admixed with a specific vaccine antigen following subcutaneous administration to mice. Material and Methods/Results: Animals were immunized with dengue virus nonstructural protein (NS1), as model antigen, in combination with native LT in the presence of LT-specific antibodies. Exposure to anti-LT antibodies did not impair the humoral adjuvanticity of LT regarding to the magnitude of the serum anti-NS1 IgG titers. In addition, anti-toxin antibodies did not reduce neutrophil migration nor edema formation after s.c. administration of LT. Nonetheless, administration of LT admixed with anti-LT antibodies changed the local cytokine production profile and modulated the NS1specific T cell responses to a Th1-type pattern. Conclusion: These results indicate that preexisting immunity does not affect the humoral adjuvant activities but may modulate different aspects of both innate and adaptive immune responses induced by parenterally administered LT.

[1]  J. Donnelly,et al.  Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. , 2001, The Journal of infectious diseases.

[2]  S. Senju,et al.  IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age , 2015, Nature Communications.

[3]  J. Clements,et al.  Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant , 2011, Clinical and Vaccine Immunology.

[4]  Christopher J. Greene,et al.  Intradermal Administration of the Type II Heat-Labile Enterotoxins LT-IIb and LT-IIc of Enterotoxigenic Escherichia coli Enhances Humoral and CD8+ T Cell Immunity to a Co-Administered Antigen , 2014, PloS one.

[5]  M. Moser,et al.  Antigen presenting cell‐derived IL‐6 restricts Th2‐cell differentiation , 2014, European journal of immunology.

[6]  Luís Carlos de Souza Ferreira,et al.  Refolded dengue virus type 2 NS1 protein expressed in Escherichia coli preserves structural and immunological properties of the native protein. , 2010, Journal of virological methods.

[7]  Pawan Kumar,et al.  Mycobacterium indicus pranii induces dendritic cell activation, survival, and Th1/Th17 polarization potential in a TLR‐dependent manner , 2015, Journal of leukocyte biology.

[8]  Lawrence H. Uricchio,et al.  Inflammasome-mediated production of IL-1β is required for neutrophil recruitment against Staphylococcus aureus in vivo. , 2008, The Journal of Immunology.

[9]  G. Glenn,et al.  GM1 Binding-Deficient Exotoxin Is a Potent Noninflammatory Broad Spectrum Intradermal Immunoadjuvant , 2006, The Journal of Immunology.

[10]  D. Nalin,et al.  Immunity to Enterotoxigenic Escherichia coli , 1979, Infection and immunity.

[11]  T. Van,et al.  Pre-existing immunity against vaccine vectors – friend or foe? , 2013, Microbiology.

[12]  D. Sack,et al.  Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407 , 2015, Clinical and Vaccine Immunology.

[13]  F. Qadri,et al.  Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country. , 2017, Vaccine.

[14]  K. Schön,et al.  The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity. , 2001, Vaccine.

[15]  T. Nagamine,et al.  Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. , 1989, Vaccine.

[16]  S. Boscardin,et al.  Parenteral Adjuvant Effects of an Enterotoxigenic Escherichia coli Natural Heat-Labile Toxin Variant , 2014, Front. Immunol..

[17]  D. Priebat,et al.  Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. , 1982, The Journal of investigative dermatology.

[18]  M. Lynch,et al.  Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. , 2005, The Journal of infectious diseases.

[19]  T. Biedermann,et al.  TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin. , 2004, The journal of investigative dermatology. Symposium proceedings.

[20]  F. Thien,et al.  Modulatory effects of alveolar macrophages on CD4+ T-cell IL-5 responses correlate with IL-1beta, IL-6, and IL-12 production. , 1999, The European respiratory journal.

[21]  T. Kishimoto,et al.  IL-6 Is Required for the Development of Th1 Cell-Mediated Murine Colitis1 , 2000, The Journal of Immunology.

[22]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[23]  T. D. Connell,et al.  Distinctive Immunomodulatory and Inflammatory Properties of the Escherichia coli Type II Heat-Labile Enterotoxin LT-IIa and Its B Pentamer following Intradermal Administration , 2011, Clinical and Vaccine Immunology.

[24]  G. Dougan,et al.  Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity , 1998, The Journal of experimental medicine.

[25]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[26]  J. H. Amorim,et al.  Functional Diversity of Heat-labile Toxins (LT) Produced by Enterotoxigenic Escherichia coli , 2010, The Journal of Biological Chemistry.

[27]  H. Dupont,et al.  Enterotoxigenic Escherichia coli heat-labile toxin seroconversion in US travelers to Mexico. , 2008, Journal of travel medicine.

[28]  B. Stoll,et al.  Local and systemic antibody responses to naturally acquired enterotoxigenic Escherichia coli diarrhea in an endemic area. , 1986, The Journal of infectious diseases.

[29]  From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis , 2015, Archives of Toxicology.

[30]  R. Rappuoli,et al.  Escherichia coli Heat-Labile Enterotoxin Promotes Protective Th17 Responses against Infection by Driving Innate IL-1 and IL-23 Production , 2011, The Journal of Immunology.

[31]  R. Rappuoli,et al.  Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin , 2009, PloS one.

[32]  J. Wrammert,et al.  Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells , 2016, mBio.

[33]  D. Vignali,et al.  Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily , 2011, Immunologic research.

[34]  S. Moghadas,et al.  Simulating Immune Interference on the Effect of a Bivalent Glycoconjugate Vaccine against Haemophilus influenzae Serotypes “a” and “b” , 2016, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[35]  James P. Nataro,et al.  Diarrheagenic Escherichia coli , 1998, Clinical Microbiology Reviews.

[36]  J. Tschopp,et al.  The neutrophil NLRC4 inflammasome selectively promotes IL-1β maturation without pyroptosis during acute Salmonella challenge. , 2014, Cell reports.

[37]  H. Wiig,et al.  Isolation of interstitial fluid from rat mammary tumors by a centrifugation method. , 2003, American journal of physiology. Heart and circulatory physiology.

[38]  R. Rappuoli,et al.  Genetically derived toxoids for use as vaccines and adjuvants. , 1999, Vaccine.

[39]  E. Fikrig,et al.  Interleukin (IL)-6 Directs the Differentiation of IL-4–producing CD4+ T Cells , 1997, The Journal of experimental medicine.

[40]  L. Ferreira,et al.  Functional and immunological characterization of a natural polymorphic variant of a heat-labile toxin (LT-I) produced by enterotoxigenic Escherichia coli (ETEC). , 2009, FEMS immunology and medical microbiology.